Literature DB >> 26029472

Inflammatory models drastically alter tumor growth and the immune microenvironment in hepatocellular carcinoma.

Geoffrey J Markowitz1, Gregory A Michelotti2, Anna Mae Diehl2, Xiao-Fan Wang1.   

Abstract

Initiation and progression of hepatocellular carcinoma (HCC) is intimately associated with a chronically diseased liver tissue. This diseased liver tissue background is a drastically different microenvironment from the healthy liver, especially with regard to immune cell prevalence and presence of mediators of immune function. To better understand the consequences of liver disease on tumor growth and the interplay with its microenvironment, we utilized two standard methods of fibrosis induction and orthotopic implantation of tumors into the inflamed and fibrotic liver to mimic the liver condition in human HCC patients. Compared to non-diseased controls, tumor growth was significantly enhanced under fibrotic conditions. The immune cells that infiltrated the tumors were also drastically different, with decreased numbers of natural killer cells but greatly increased numbers of immune-suppressive CD11b+ Gr1hi myeloid cells in both models of fibrosis. In addition, there were model-specific differences: Increased numbers of CD11b+ myeloid cells and CD4+ CD25+ T cells were found in tumors in the bile duct ligation model but not in the carbon tetrachloride model. Induction of fibrosis altered the cytokine production of implanted tumor cells, which could have farreaching consequences on the immune infiltrate and its functionality. Taken together, this work demonstrates that the combination of fibrosis induction with orthotopic tumor implantation results in a markedly different tumor microenvironment and tumor growth kinetics, emphasizing the necessity for more accurate modeling of HCC progression in mice, which takes into account the drastic changes in the tissue caused by chronic liver disease.

Entities:  

Keywords:  Bile duct ligation; Carbon tetrachloride; Cytokines; Fibrosis; Hepatocellular carcinoma; Tumor microenvironment

Year:  2015        PMID: 26029472      PMCID: PMC4445464          DOI: 10.1007/s11434-015-0772-5

Source DB:  PubMed          Journal:  Sci Bull (Beijing)        ISSN: 2095-9273            Impact factor:   11.780


  46 in total

Review 1.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

2.  Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling.

Authors:  Guobin He; Debanjan Dhar; Hayato Nakagawa; Joan Font-Burgada; Hisanobu Ogata; Yuhong Jiang; Shabnam Shalapour; Ekihiro Seki; Shawn E Yost; Kristen Jepsen; Kelly A Frazer; Olivier Harismendy; Maria Hatziapostolou; Dimitrios Iliopoulos; Atsushi Suetsugu; Robert M Hoffman; Ryosuke Tateishi; Kazuhiko Koike; Michael Karin
Journal:  Cell       Date:  2013-10-10       Impact factor: 41.582

3.  Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer.

Authors:  Carlo Schneider; Andreas Teufel; Tetyana Yevsa; Frank Staib; Anja Hohmeyer; Gudrun Walenda; Henning W Zimmermann; Mihael Vucur; Sebastian Huss; Nikolaus Gassler; Hermann E Wasmuth; Sergio A Lira; Lars Zender; Tom Luedde; Christian Trautwein; Frank Tacke
Journal:  Gut       Date:  2012-01-20       Impact factor: 23.059

4.  The hepatitis B virus-associated tumor microenvironment in hepatocellular carcinoma.

Authors:  Pengyuan Yang; Geoffrey J Markowitz; Xiao-Fan Wang
Journal:  Natl Sci Rev       Date:  2014-07-14       Impact factor: 17.275

5.  Direct and indirect contribution of human embryonic stem cell-derived hepatocyte-like cells to liver repair in mice.

Authors:  Dong-Hun Woo; Suel-Kee Kim; Hee-Joung Lim; Jeonghoon Heo; Hyung Soon Park; Gum-Yong Kang; Sung-Eun Kim; Hyun-Ju You; Daniel J Hoeppner; Youngchul Kim; Heechung Kwon; Tae Hyun Choi; Joo Hee Lee; Su Hee Hong; Kang Won Song; Eun-Kyung Ahn; Josh G Chenoweth; Paul J Tesar; Ronald D G McKay; Jong-Hoon Kim
Journal:  Gastroenterology       Date:  2011-12-02       Impact factor: 22.682

6.  Tumor microenvironments direct the recruitment and expansion of human Th17 cells.

Authors:  Xinming Su; Jian Ye; Eddy C Hsueh; Yanping Zhang; Daniel F Hoft; Guangyong Peng
Journal:  J Immunol       Date:  2009-12-21       Impact factor: 5.422

7.  Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality.

Authors:  Suresh Kalathil; Amit A Lugade; Austin Miller; Renuka Iyer; Yasmin Thanavala
Journal:  Cancer Res       Date:  2013-02-19       Impact factor: 12.701

8.  Gene expression in fixed tissues and outcome in hepatocellular carcinoma.

Authors:  Yujin Hoshida; Augusto Villanueva; Masahiro Kobayashi; Judit Peix; Derek Y Chiang; Amy Camargo; Supriya Gupta; Jamie Moore; Matthew J Wrobel; Jim Lerner; Michael Reich; Jennifer A Chan; Jonathan N Glickman; Kenji Ikeda; Masaji Hashimoto; Goro Watanabe; Maria G Daidone; Sasan Roayaie; Myron Schwartz; Swan Thung; Helga B Salvesen; Stacey Gabriel; Vincenzo Mazzaferro; Jordi Bruix; Scott L Friedman; Hiromitsu Kumada; Josep M Llovet; Todd R Golub
Journal:  N Engl J Med       Date:  2008-10-15       Impact factor: 91.245

9.  A lymphotoxin-driven pathway to hepatocellular carcinoma.

Authors:  Johannes Haybaeck; Nicolas Zeller; Monika Julia Wolf; Achim Weber; Ulrich Wagner; Michael Odo Kurrer; Juliane Bremer; Giandomenica Iezzi; Rolf Graf; Pierre-Alain Clavien; Robert Thimme; Hubert Blum; Sergei A Nedospasov; Kurt Zatloukal; Muhammad Ramzan; Sandra Ciesek; Thomas Pietschmann; Patrice N Marche; Michael Karin; Manfred Kopf; Jeffrey L Browning; Adriano Aguzzi; Mathias Heikenwalder
Journal:  Cancer Cell       Date:  2009-10-06       Impact factor: 31.743

10.  Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice.

Authors:  Yunching Chen; Yuhui Huang; Thomas Reiberger; Annique M Duyverman; Peigen Huang; Rekha Samuel; Lotte Hiddingh; Sylvie Roberge; Christina Koppel; Gregory Y Lauwers; Andrew X Zhu; Rakesh K Jain; Dan G Duda
Journal:  Hepatology       Date:  2014-02-18       Impact factor: 17.425

View more
  4 in total

1.  Inflammation-Dependent IL18 Signaling Restricts Hepatocellular Carcinoma Growth by Enhancing the Accumulation and Activity of Tumor-Infiltrating Lymphocytes.

Authors:  Geoffrey J Markowitz; Pengyuan Yang; Jing Fu; Gregory A Michelotti; Rui Chen; Jianhua Sui; Bin Yang; Wen-Hao Qin; Zheng Zhang; Fu-Sheng Wang; Anna Mae Diehl; Qi-Jing Li; Hongyang Wang; Xiao-Fan Wang
Journal:  Cancer Res       Date:  2016-02-18       Impact factor: 12.701

2.  C-reactive protein/albumin and neutrophil/lymphocyte ratios and their combination predict overall survival in patients with gastric cancer.

Authors:  Minjie Mao; Xiaoli Wei; Hui Sheng; Peidong Chi; Yijun Liu; Xiaoyan Huang; Yifan Xiang; Qianying Zhu; Shan Xing; Wanli Liu
Journal:  Oncol Lett       Date:  2017-10-13       Impact factor: 2.967

3.  Antitumor necrosis factor-α antibodies as a noveltherapy for hepatocellular carcinoma.

Authors:  Wei Li; Yong-Bin Jian
Journal:  Exp Ther Med       Date:  2018-05-30       Impact factor: 2.447

4.  Intrahepatic Tissue Implantation Represents a Favorable Approach for Establishing Orthotopic Transplantation Hepatocellular Carcinoma Mouse Models.

Authors:  Quan Rao; Abin You; Zhenglong Guo; Bingfeng Zuo; Xianjun Gao; Ti Zhang; Zhi Du; Chenxuan Wu; HaiFang Yin
Journal:  PLoS One       Date:  2016-01-29       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.